AlloVir (ALVR) Stock Price, News & Analysis

Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $0.56 to $0.64
• 50-Day Range: $0.54 to $1.01
• 52-Week Range: $0.52 to $2.49
• Volume: 645,131 shs
• Average Volume: 617,220 shs
• Market Capitalization: $65.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

AlloVir Stock Analysis - MarketRank™

AlloVir scored higher than 47% of companies evaluated by MarketBeat, and ranked 639th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for AlloVir.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AlloVir is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AlloVir is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AlloVir has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.42% of the outstanding shares of AlloVir have been sold short.

Short Interest Ratio / Days to Cover

AlloVir has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.

Change versus previous month

Short interest in AlloVir has recently decreased by 19.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AlloVir does not currently pay a dividend.

Dividend Growth

AlloVir does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.42% of the outstanding shares of AlloVir have been sold short.

Short Interest Ratio / Days to Cover

AlloVir has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.

Change versus previous month

Short interest in AlloVir has recently decreased by 19.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 2.09

News Sentiment

AlloVir has a news sentiment score of 2.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for AlloVir this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for ALVR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

8 people have added AlloVir to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,284.00 in company stock.

Percentage Held by Insiders

33.85% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALVR Stock Analysis - Frequently Asked Questions

How have ALVR shares performed this year?

AlloVir's stock was trading at $0.6798 at the beginning of 2024. Since then, ALVR shares have decreased by 16.1% and is now trading at $0.5701.
View the best growth stocks for 2024 here.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) announced its earnings results on Tuesday, November, 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10.

When did AlloVir IPO?

AlloVir (ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are AlloVir's major shareholders?

AlloVir's top institutional investors include Geode Capital Management LLC (0.51%), Jane Street Group LLC (0.07%) and Charles Schwab Investment Management Inc. (0.05%). Insiders that own company stock include Gilead Sciences, Inc, Diana Brainard, Beek Jeroen B Van, Edward Miller, David Hallal, Brett R Hagen, Jeffrey S Bornstein and Ercem Atillasoy.
View institutional ownership trends.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/21/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVR
• CUSIP: N/A
• CIK: 1754068
• Web: www.allovir.com
• Phone: 617-433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-190,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.03%
• Return on Assets: -61.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 86.78
• Quick Ratio: 86.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.28 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 115,537,000
• Free Float: 76,428,000
• Market Cap: $65.87 million
• Optionable: Optionable
• Beta: 0.75